DOCSLIB.ORG

Key Messages – Zika Virus Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Key Messages – Zika Virus Disease 10/6/17 FOR EXTERNAL USE KEY MESSAGES – ZIKA VIRUS DISEASE Purpose: This document is for internal and external use. The document contains cleared key messages for use in developing other materials. Information in this document is current as of October 6, 2017. No further updates will be provided. For the latest information on Zika, please visit www.cdc.gov/Zika. Updated information is in blue. CONTENTS Background on Zika...................................................................................................................................................................... 2 Outbreak Summary ...................................................................................................................................................................... 3 Symptoms .................................................................................................................................................................................... 3 Transmission ................................................................................................................................................................................ 3 Mosquito (Vector) Transmission ............................................................................................................................................. 4 Mosquitoes and Hurricanes ................................................................................................................................................. 6 Periconceptional/Intrauterine/Perinatal transmission ........................................................................................................... 6 Sexual Transmission ................................................................................................................................................................ 7 Blood Transfusion .................................................................................................................................................................... 8 Breastfeeding .......................................................................................................................................................................... 8 Testing & Diagnosis ...................................................................................................................................................................... 8 Treatment .................................................................................................................................................................................... 9 Prevention ................................................................................................................................................................................... 9 Preventing Mosquito Transmission of Zika Virus .................................................................................................................. 10 Insect Repellent ................................................................................................................................................................. 10 Mosquito Control at Home ................................................................................................................................................ 11 Mosquito Control during an Outbreak .............................................................................................................................. 12 Integrated Mosquito Control ............................................................................................................................................. 12 Mosquito Surveillance and Control Methods and Tools.................................................................................................... 12 Preventing Sexual Transmission ............................................................................................................................................ 15 Preventing Zika Infection in Pregnancy ................................................................................................................................. 16 Recommendations for Couples Interested in Conceiving .................................................................................................. 17 Preventing Unintended Pregnancy during the Zika Virus Outbreak ..................................................................................... 18 Zika Virus Blood & Tissue Safety ........................................................................................................................................... 19 Puerto Rico Survey of Blood Collection Centers ................................................................................................................ 19 Health Effects Associated with Zika ........................................................................................................................................... 20 1 10/6/17 FOR EXTERNAL USE Microcephaly ......................................................................................................................................................................... 21 Diagnosis of Microcephaly ................................................................................................................................................. 21 Pyriproxyfen ....................................................................................................................................................................... 22 Guillain-Barré Syndrome ............................................................................................................................................................ 22 Zika & the United States ............................................................................................................................................................ 22 Zika Pregnancy Registries ...................................................................................................................................................... 23 National Reporting: Pregnant Women & outcomes ............................................................................................................. 23 Zika & US Territories .................................................................................................................................................................. 25 Zika & Colombia ......................................................................................................................................................................... 26 international Travel Recommendations .................................................................................................................................... 27 International and Overseas US Territory Travel Notices ....................................................................................................... 28 Domestic Travel Guidance (applies to continental United States and Hawaii) ..................................................................... 28 CDC Guidance & Recommendations for Healthcare Providers ................................................................................................. 29 Obstetrical Healthcare Providers .......................................................................................................................................... 29 Prenatal Diagnosis of Congenital Zika Virus Infection ....................................................................................................... 30 Pediatric Healthcare Providers .............................................................................................................................................. 32 Birth Defects ...................................................................................................................................................................... 32 Potential Outcomes & Prognosis ....................................................................................................................................... 33 Clinical Guidance ................................................................................................................................................................ 33 Infection Control ................................................................................................................................................................... 35 Laboratory Testing ..................................................................................................................................................................... 35 Types of Tests ........................................................................................................................................................................ 36 Testing for Non-Pregnant Women and Men ......................................................................................................................... 37 Testing for Pregnant Women ................................................................................................................................................ 37 Testing for Congenital Zika Virus Infection ............................................................................................................................ 38 Pathology Testing .................................................................................................................................................................. 39 What CDC
Load more

Recommended publications
  • Executive Orders and Emergency Declarations for the West Nile Virus: Applying Lessons from Past Outbreaks to Zika
    Executive Orders and Emergency Declarations for the West Nile Virus: Applying Lessons from Past Outbreaks to Zika Government leaders are often given the authority to issue executive orders (EOs), proclamations, or emergency declarations to address public health threats, such as that posed by the Zika virus.1 Local, state, and federal executive branch leaders have used these powers to address public health threats posed by other mosquito-borne diseases.2 While existing laws and regulations may allow localities, states, and the federal government to take action to combat mosquito-borne threats absent an EO or emergency declaration, examining such executive actions provides a snapshot of how some jurisdictions have responded to past outbreaks. As of February 21, 2016, only one territory and two states (Puerto Rico, Florida, and Hawaii) have issued emergency declarations that contemplate the threats posed by the Zika virus.3, 4 Historically, however, many US jurisdictions have taken such actions to address other mosquito-borne illnesses, such as West Nile virus. The following provides a brief analysis of select uses of local, state, and federal executive powers to combat West Nile virus. Examining the use of executive powers to address West 1 L Rutkow et al. The Public Health Workforce and Willingness to Respond to Emergencies: A 50-State Analysis of Potentially Influential Laws, 42 J. LAW MED. & ETHICS 64, 64 (2014) (“In the United States, at the federal, state, and local levels, laws provide an infrastructure for public health emergency preparedness and response efforts. Law is perhaps most visible during an emergency when the president or a state’s governor issues a disaster declaration establishing the temporal and geographic parameters for the response and making financial and other resources available.”).
    [Show full text]
  • Asian Zika Virus Isolate Significantly Changes the Transcriptional Profile
    viruses Article Asian Zika Virus Isolate Significantly Changes the Transcriptional Profile and Alternative RNA Splicing Events in a Neuroblastoma Cell Line Gaston Bonenfant 1,2, Ryan Meng 2, Carl Shotwell 2,3 , Pheonah Badu 1,2, Anne F. Payne 4, Alexander T. Ciota 4,5, Morgan A. Sammons 1, J. Andrew Berglund 1,2 and Cara T. Pager 1,2,* 1 Department of Biological Sciences, University at Albany-SUNY, Albany, NY 12222, USA; [email protected] (G.B.); [email protected] (P.B.); [email protected] (M.A.S.); [email protected] (J.A.B.) 2 The RNA Institute, University at Albany-SUNY, Albany, NY 12222, USA; [email protected] (R.M.); [email protected] (C.S.) 3 Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, FL 32610, USA 4 Wadsworth Center, New York State Department of Health (NYSDOH), Slingerlands, NY 12159, USA; [email protected] (A.F.P.); [email protected] (A.T.C.) 5 Department of Biomedical Sciences, University at Albany-SUNY, School of Public Health, Rensselaer, NY 12144, USA * Correspondence: [email protected]; Tel.: +1-518-591-8841 Received: 9 April 2020; Accepted: 27 April 2020; Published: 5 May 2020 Abstract: The alternative splicing of pre-mRNAs expands a single genetic blueprint to encode multiple, functionally diverse protein isoforms. Viruses have previously been shown to interact with, depend on, and alter host splicing machinery. The consequences, however, incited by viral infection on the global alternative slicing (AS) landscape are under-appreciated. Here, we investigated the transcriptional and alternative splicing profile of neuronal cells infected with a contemporary Puerto Rican Zika virus (ZIKVPR) isolate, an isolate of the prototypical Ugandan ZIKV (ZIKVMR), and dengue virus 2 (DENV2).
    [Show full text]
  • First Draft of an Epidemic: How Key Media Players Framed Zika
    Reuters Institute Fellowship Paper University of Oxford First draft of an epidemic: how key media players framed Zika by Maria Cleidejane Esperidião Hilary Term, 2018 Sponsor: Thomson Reuters Foundation 1 TABLE OF CONTENTS Acknowledgements…………………………………………………………… …4 Abstract………………………………………………………………………………5 Introduction…………………………………………………………………………6. Chapter One: Covering Epidemics……………………………………………….9 1.1 Understanding a framework……………………………………………….9 1.2 Fear, risk and threat………………………………………………………..12. Chapter Two: Zika: Examining national and global context………………. 15 2.1 Zika Virus: links to microcephaly and other neurological disorders..15 2.2 Science in transition………………………………………………..………16. 2.3 Brazil and the world in transition……………………………………..…18 Chapter Three: Framing Zika…………………………………………………....25. 3.1 Methodology and theoretical framework……………………………… 25. 3.2 How did we collected the data?..................................................................27. 3.3 Findings: from global threat to regional disaster………………………29 3.3.1 The case of Al-Jazeera………………………………………………….29 3.3.2 The case of BBC…………………………………………………………33 3.3.3 The case of CNN………………………………………………………..40 Conclusions, Limitations and Recommendations…………………………… 51 Bibliography……………………………………………………………………….54 Appendixes………………………………………………………………………...58 2 I suppose, in the end, we journalists try—or should try—to be the first impartial witnesses to history. If we have any reason for our existence, the least must be our ability to report history as it happens so that no one can say: “We
    [Show full text]
  • Zika Virus Outside Africa Edward B
    Zika Virus Outside Africa Edward B. Hayes Zika virus (ZIKV) is a flavivirus related to yellow fever, est (4). Serologic studies indicated that humans could also dengue, West Nile, and Japanese encephalitis viruses. In be infected (5). Transmission of ZIKV by artificially fed 2007 ZIKV caused an outbreak of relatively mild disease Ae. aegypti mosquitoes to mice and a monkey in a labora- characterized by rash, arthralgia, and conjunctivitis on Yap tory was reported in 1956 (6). Island in the southwestern Pacific Ocean. This was the first ZIKV was isolated from humans in Nigeria during time that ZIKV was detected outside of Africa and Asia. The studies conducted in 1968 and during 1971–1975; in 1 history, transmission dynamics, virology, and clinical mani- festations of ZIKV disease are discussed, along with the study, 40% of the persons tested had neutralizing antibody possibility for diagnostic confusion between ZIKV illness to ZIKV (7–9). Human isolates were obtained from febrile and dengue. The emergence of ZIKV outside of its previ- children 10 months, 2 years (2 cases), and 3 years of age, ously known geographic range should prompt awareness of all without other clinical details described, and from a 10 the potential for ZIKV to spread to other Pacific islands and year-old boy with fever, headache, and body pains (7,8). the Americas. From 1951 through 1981, serologic evidence of human ZIKV infection was reported from other African coun- tries such as Uganda, Tanzania, Egypt, Central African n April 2007, an outbreak of illness characterized by rash, Republic, Sierra Leone (10), and Gabon, and in parts of arthralgia, and conjunctivitis was reported on Yap Island I Asia including India, Malaysia, the Philippines, Thailand, in the Federated States of Micronesia.
    [Show full text]
  • Ninth Meeting of the WHO Vector Control Advisory Group
    MEETING REPORT 12-14 November 2018 Ninth meeting of the WHO Vector Control Advisory Group MEETING REPORT 12-14 November 2018 Ninth meeting of the WHO Vector Control Advisory Group WHO/CDS/VCAG/2018.05 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or ervics es. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Ninth meeting of the WHO Vector Control Advisory Group. Geneva: World Health Organization; 2018 (WHO/CDS/VCAG/2018.05). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • An Overview of Mosquito Vectors of Zika Virus
    Microbes and Infection xxx (2018) 1e15 Contents lists available at ScienceDirect Microbes and Infection journal homepage: www.elsevier.com/locate/micinf An overview of mosquito vectors of Zika virus Sebastien Boyer a, Elodie Calvez b, Thais Chouin-Carneiro c, Diawo Diallo d, * Anna-Bella Failloux e, a Institut Pasteur of Cambodia, Unit of Medical Entomology, Phnom Penh, Cambodia b Institut Pasteur of New Caledonia, URE Dengue and Other Arboviruses, Noumea, New Caledonia c Instituto Oswaldo Cruz e Fiocruz, Laboratorio de Transmissores de Hematozoarios, Rio de Janeiro, Brazil d Institut Pasteur of Dakar, Unit of Medical Entomology, Dakar, Senegal e Institut Pasteur, URE Arboviruses and Insect Vectors, Paris, France article info abstract Article history: The mosquito-borne arbovirus Zika virus (ZIKV, Flavivirus, Flaviviridae), has caused an outbreak Received 6 December 2017 impressive by its magnitude and rapid spread. First detected in Uganda in Africa in 1947, from where it Accepted 15 January 2018 spread to Asia in the 1960s, it emerged in 2007 on the Yap Island in Micronesia and hit most islands in Available online xxx the Pacific region in 2013. Subsequently, ZIKV was detected in the Caribbean, and Central and South America in 2015, and reached North America in 2016. Although ZIKV infections are in general asymp- Keywords: tomatic or causing mild self-limiting illness, severe symptoms have been described including neuro- Arbovirus logical disorders and microcephaly in newborns. To face such an alarming health situation, WHO has Mosquito vectors Aedes aegypti declared Zika as an emerging global health threat. This review summarizes the literature on the main fi Vector competence vectors of ZIKV (sylvatic and urban) across all the ve continents with special focus on vector compe- tence studies.
    [Show full text]
  • Genetically Modified Mosquitoes Educator Materials
    Genetically Modified Mosquitoes Scientists at Work Educator Materials OVERVIEW This document provides background information, discussion questions, and responses that complement the short video “Genetically Modified Mosquitoes” from the Scientists at Work series. The Scientists at Work series is intended to provide insights into the daily work of scientists that builds toward discoveries. The series focuses especially on scientists in the field and what motivates their work. This 8-minute 35-second video is appropriate for any life science student audience. It can be used as a review of the nature of science or to enhance a discussion on transgenic technology. Classroom implementation of the material in this document might include assigning select discussion questions to small groups of students or selecting the top five questions to discuss as a class. KEY CONCEPTS • Researchers genetically modified mosquitoes to help prevent the spread of a virus. • Male GM mosquitoes pass on a lethality gene to the offspring when they mate with non-GM females in the wild. CURRICULUM CONNECTIONS Standards Curriculum Connection NGSS (2013) HS-LS1.A, HS-LS3.A AP Bio (2015) 3.A.1 IB Bio (2016) 3.1, 3.5 Vision and Change (2009) CC1, CC2, CC3 PRIOR KNOWLEDGE Students should • be familiar with the idea that genes code for proteins and that genetic information can be passed to offspring. • have some understanding of transgenic technology and what it means for an organism to be genetically modified. BACKGROUND INFORMATION Mosquitoes can transmit pathogens that cause many human diseases, such as malaria, yellow fever, dengue fever, chikungunya, and Zika fever.
    [Show full text]
  • Division of Disease Control Pump Handle
    "I had an interview with the Board of Guardians of St. James's parish, on the evening of Thursday, 7th September, and represented the above circumstances to them. In consequence of what I said, the handle of the pump was removed on the following day." John Snow, 1855 April 2016 Topics Rabies Update – Laura Cronquist Disease Control Is Amassing a Small Army of Students – Tracy Miller Zika Virus Update – Laura Cronquist New Disease Control Employee! Rabies Update As of May 16, 2016, nine animals have tested positive for rabies in North Dakota, including five skunks, three cows, and one cat. Six animals tested positive for rabies in 2015, but over the previous five years, an average of 31 animals per year tested positive for rabies. North Dakota Department of Health (NDDoH) surveillance data from the past 20 years shows that skunks make up the majority of animal rabies cases in the state. While all species of mammals are susceptible to rabies virus infection, over 90% of all animal rabies cases reported to the Centers for Disease Control and Prevention (CDC) occur in wild animals. Skunks, bats, raccoons, and foxes are the animals that most often get rabies in the United States. Skunks and raccoons are particularly important as reservoirs for the rabies virus, which is the rationale behind a state law prohibiting North Dakotans from keeping a skunk or raccoon in captivity. One of the best ways to protect yourself and others from rabies is by making sure that your pets are vaccinated. Contact your veterinarian to find out whether your pets are up-to-date on their rabies vaccinations.
    [Show full text]
  • Dengue Fever, Chikungunya and the Zika Virus
    #57 Focus Dengue Fever, Chikungunya and the Zika Virus Arboviruses are a group of virus that can be southern regions of mainland France and transmitted between animals and humans, on the island of Réunion, Aedes albopictus and they are common to humans and many provides the sole vector for transmission. vertebrates (mammals, birds, reptiles, Transmission amphibians). There are over 500 species of Dengue Fever, Chikungunya and the Zika arbovirus, sub-divided into approximately virus are all transmitted in the same way. 10 different families, including Togaviridae, Human to human transmission takes place Flaviviridae, Reoviridae, Rhabdoviridae, International and Bunyaviridae. These viruses have RNA by mosquito vector in urban areas during with a very heterogeneous structure and are epidemics: the mosquito picks up the virus transmitted via bites from hematophagous when it bites a carrier, and then transmits it arthropods such as mosquitoes, sandflies, to a healthy person with another bite. The ticks and mites (arbovirus is short for mosquito bites people outside their homes arthropod-borne virus). throughout the day, with peak activity at dawn and dusk. The mosquitoes live in Chikungunya urban areas and lay their eggs in pools of stagnant water (250 eggs every 2 days), This disease was first described in Tanzania where they develop into larvae. The eggs in 1952. It is caused by an arbovirus of the are resistant to the cold in winter and hatch genus Alphavirus from the Togaviridae family. when weather conditions improve. It was then also described in Africa, Southeast Aedes albopictus is spreading globally; it Asia, the Indian subcontinent and the Indian has adapted to both tropical and temperate Ocean.
    [Show full text]
  • Zika Virus E an Overview
    + MODEL Microbes and Infection xx (2016) 1e7 www.elsevier.com/locate/micinf Review Zika virus e an overview Camila Zanluca, Claudia Nunes Duarte dos Santos* Laboratorio de Virologia Molecular, Instituto Carlos Chagas, Fundaçao~ Oswaldo Cruz, Curitiba, PR, Brazil Received 14 February 2016; accepted 3 March 2016 Available online ▪▪▪ Abstract Zika virus (ZIKV) is currently one of the most important emerging viruses in the world. Recently, it has caused outbreaks and epidemics, and has been associated with severe clinical manifestations and congenital malformations. However to date, little is known about the pathogenicity of the virus and the consequences of ZIKV infection. In this paper, we provide an overview of the current knowledge on ZIKV. © 2016 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved. Keywords: Zika virus; Flavivirus; Arthropod-borne virus; Viral emergence 1. Introduction 2. Epidemiology Zika virus (ZIKV) is an arthropod-born virus (arbovirus) Zika virus was first isolated in 1947 from the serum of a belonging to the genus Flavivirus and the family Flaviviridae sentinel Rhesus monkey from the Zika Forest (Uganda) during [1]. The virus carries the name of the forest where it was first a study on the transmission of yellow fever. The second identified [2], a name that means “overgrown” in the Luganda isolation was made from a pool of Aedes (Stegomyia) africa- language [3]. nus mosquitoes from the same forest in 1948 [2]. The occur- Beyond ZIKV, the genus Flavivirus comprises 52 other rence of human infection was first evidenced by the presence viral species, including the dengue, yellow fever, Saint Louis of neutralising antibodies in the sera of east African residents encephalitis and West Nile viruses [1].
    [Show full text]
  • Dengue Fever/Severe Dengue Fever/Chikungunya Fever! Report on Suspicion of Infection During Business Hours
    Dengue Fever/Severe Dengue Fever/Chikungunya Fever! Report on suspicion of infection during business hours PROTOCOL CHECKLIST Enter available information into Merlin upon receipt of initial report Review background information on the disease (see Section 2), case definitions (see Section 3 for dengue and for chikungunya), and laboratory testing (see Section 4) Forward specimens to the Florida Department of Health (DOH) Bureau of Public Health Laboratories (BPHL) for confirmatory laboratory testing (as needed) Inform local mosquito control personnel of suspected chikungunya or dengue case as soon as possible (if applicable) Inform state Arbovirus Surveillance Coordinator on suspicion of locally acquired arbovirus infection Contact provider (see Section 5A) Interview case-patient Review disease facts (see Section 2) Mode of transmission Ask about exposure to relevant risk factors (see Section 5. Case Investigation) History of travel, outdoor activities, and mosquito bites two weeks prior to onset History of febrile illness or travel for household members or other close contacts in the month prior to onset History of previous arbovirus infection or vaccination (yellow fever, Japanese encephalitis) Provide education on transmission and prevention (see Section 6) Awareness of mosquito-borne diseases Drain standing water at least weekly to stop mosquitoes from multiplying Discard items that collect water and are not being used Cover skin with clothing or Environmental Protection Agency (EPA)-registered repellent such as DEET (N,N-diethyl-meta-toluamide) Use permethrin on clothing (not skin) according to manufacturer’s directions Cover doors and windows with intact screens to keep mosquitoes out of the house Enter additional data obtained from interview into Merlin (see Section 5D) Arrange for a convalescent specimen to be taken (if necessary) Dengue/Chikungunya Guide to Surveillance and Investigation Dengue Fever/Severe Dengue/Chikungunya 1.
    [Show full text]
  • Oxitec's Genetically Modified Mosquitoes: Ongoing Concerns
    Oxitec’s Genetically Modified Mosquitoes: Ongoing Concerns August 2012 UK biotech company Oxitec has released millions of genetically modified (GM) mosquitoes in Brazil, following smaller experiments in the Cayman Islands and Malaysia. Further experiments are planned in Brazil on an even larger scale. The company also hopes to conduct experimental releases in Panama, the USA (Florida Keys), India, Sri Lanka and perhaps other countries. Oxitec’s patented technique for genetically modifying insects is known as RIDL (Release of Insects carrying a Dominant Lethal genetic system). 1 All the company’s open field experiments to date involve its OX513A strain of the Aedes aegypti mosquito, which is genetically engineered to contain a red fluorescent marker and the RIDL ‘conditional lethality’ trait. Oxitec’s male OX513A GM mosquitoes are intended to mate with wild females and produce offspring which die as larvae. Releases of large numbers of GM males, vastly outnumbering the wild male mosquito population, are intended to reduce the total adult population of mosquitoes over time, as many of the GM offspring fail to survive to adulthood. The GM mosquitoes released in the experiments are Yellow Fever mosquitoes ( Aedes aegypti ) which transmit the tropical disease dengue fever. No risk assessment was published for public scrutiny or consultation prior to releases of GM mosquitoes in the Cayman Islands or Brazil. In Malaysia only a summary was published. GeneWatch has obtained copies of the risk assessments in the UK because they must be provided by Oxitec when exporting GM mosquito eggs for open release for the first time to a given country.
    [Show full text]